Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Dyshidrotic Eczema

  • Author: Sadegh Amini, MD; Chief Editor: William D James, MD  more...
 
Updated: Feb 26, 2016
 

Background

Dyshidrotic eczema is a type of eczema (dermatitis) of unknown cause that is characterized by a pruritic vesicular eruption on the fingers, palms, and soles. The condition affects teenagers and adults and may be acute, recurrent, or chronic. A more appropriate term for this vesicular eruption is pompholyx, which means bubble. The clinical course of dyshidrotic eczema can range from self-limited to chronic, severe, or debilitating. The condition's unresponsiveness to treatment can be frustrating for the patient and physician (see the images below).

Tense vesicles and bullae on the palm. Courtesy of Tense vesicles and bullae on the palm. Courtesy of Norman Minars, MD, University of Miami, Department of Dermatology & Cutaneous Surgery.
Multiple tense vesicles on the palm. Multiple tense vesicles on the palm.

Some believe the terms pompholyx and dyshidrosis are obsolete and favor a new term, such as "acute and recurrent vesicular hand dermatitis." The etiology of dyshidrotic eczema is unresolved and is believed to be multifactorial. Dyshidrotic eczema is considered to be a reaction pattern caused by various endogenous conditions and exogenous factors.

See All About Allergies: Be Ready for Spring, a Critical Images slideshow, to help identify a variety of allergens and symptoms.

Complications

Secondary bacterial infection of dyshidrotic eczema vesicles or bullae can result in cellulitis, lymphangitis, and septicemia (rare). Dystrophic nail changes may develop, with the occurrence of transverse ridging, thickening, discoloration, and pitting. Dyshidrotic eczema has no associated mortality, although some severe cases can become debilitating. (See Clinical.) A 2015 study determined that dyshidrosis is a risk factor in the development of herpes zoster. Because of the strong association between the two conditions, the authors have suggested that patients should be warned about the risk.[1]

Prognosis

Dyshidrotic eczema follows a chronic, intermittent course, with fewer episodes occurring after middle age. Some mildly affected patients experience spontaneous resolution within 2-3 weeks. (See Treatment and Medication.)

Patient education

Instruct dyshidrotic eczema patients to avoid contact with certain allergens or irritants (eg, nickel), to follow a hand care routine that avoids irritants, and to use emollients regularly. In addition, inform individuals with this disorder about the difficulty of achieving successful treatment. For patient education information, see the Skin Conditions and Beauty Center, as well as Eczema (Atopic Dermatitis). (See Treatment and Medication.)

Severity index

The Dyshidrotic Eczema Area and Severity Index was developed based on severity grades for the number of vesicles per square centimeter, erythema, desquamation, itch, and the extent of affected areas.[2] The index was found to be a simple standardized method for assessing the condition and was used to assess disease severity and treatment effectiveness in 2 clinical studies. Further evaluation with larger patient groups is needed.

Next

Etiology

The hypothesis of sweat gland dysfunction has been disputed because vesicles have not been shown to be associated with sweat ducts. A 2009 case report provided clear histopathologic evidence that sweat glands do not play a role in dyshidrosis.[3] However, hyperhidrosis is an aggravating factor in 40% of patients with dyshidrotic eczema. Improvement in pruritus, erythema, vesicles, and hand dermatitis with fewer or no signs of relapse has been obtained after botulinum toxin A injection.[4]

Dyshidrotic eczema may be associated with atopy and familial atopy. Of patients with dyshidrosis, 50% have atopic dermatitis.

Exogenous factors (eg, contact dermatitis to nickel, balsam, cobalt; sensitivity to ingested metals; dermatophyte infection; bacterial infection) may trigger episodes. These antigens may act as haptens with a specific affinity for palmoplantar proteins of the stratum lucidum of the epidermis. The binding of these haptens to tissue receptor sites may initiate pompholyx.

Evidence shows that the ingestion of metal ions such as cobalt can induce type I and type IV hypersensitivity reactions. In addition, they can also act as atypical haptens, activating T lymphocytes through human leukocyte antigen–independent pathways, causing systemic allergic dermatitis in the form of dyshidrotic eczema.[5, 6]

Emotional stress[7] and environmental factors (eg, seasonal changes, hot or cold temperatures, humidity) reportedly exacerbate dyshidrosis. In addition, dyshidrosislike eczematous eruptions with the use of intravenous immunoglobulin infusions have been reported.

Dyshidrosislike eczematous eruptions with the use of intravenous immunoglobulin (IVIG) infusions have been reported. A recent search of the literature identified pompholyx as one of the most important cutaneous adverse effects of IVIG, being present in 62.5% of the patients reported, with 75% of those patients developing the lesions after just one IVIG treatment.[8] The eruption tends to be mild and to wane over time. It usually responds very well to topical steroids,[9, 10, 11]  but it may become recurrent and more aggressive after repeated doses of IVIG.

In some patients, a distant fungal infection can cause palmar pompholyx as an id reaction. In one study, one third of pompholyx occurrences on the palms resolved after treatment for tinea pedis. The factors believed to be associated with dyshidrotic eczema are discussed in more detail below.

Genetic factors

Monozygotic twins have been affected simultaneously by dyshidrotic eczema. The pompholyx gene has been mapped to band 18q22.1-18q22.3 in the autosomal dominant form of familial pompholyx.[12]

Mutations on the filaggrin gene leading to loss of filaggrin, a structural protein of the stratum corneum involved in the barrier function of the skin, causes dyskeratinization, increased transepidermal water loss, and an increase in the transepidermal antigen transfer. Combined, these features have been associated with the development of icthyosis and atopic dermatitis, and they may be involved in the development of irritant and allergic contact dermatitis, which are well-known conditions associated with dyshidrotic eczema. Chronic hand dermatitis, including dyshidrotis eczema, has also been associated with defects in the skin barrier, and, in a few cases, it has been also associated with mutations in the filaggrin gene; however, these have not reached statistical significance.[13]

Aquaporins have been shown to be expressed in patients with atopic dermatitis and may also be related to exacerbation and chronicity of pompholyx. Aquaporins are channel proteins located on cell membranes that increase their permeability, in particular aquaglyceroporins. Aquaglyceroporins can transport water and glycerol. Aquaporin-3 and aquaporin-10 are normally expressed in the basal layer of the epidermis, and immunohistochemical staining had demonstrated their presence in all epidermal layers in patients with pompholyx. These channels may participate in the increase of transepidermal water loss seen in atopic dermatitis and possibly in pompholyx. Owing to osmotic gradients, among other factors, the direction of water and glycerol through aquaporins is from the skin to the environment, possibly contributing with skin dehydration, even immediately after hand washing. Hypothetically, topical and/or systemic inhibition of the expression of aquaporins in the epidermis could contribute with the preservation of water and glycerol, decreasing the frequency and severity of pompholyx exacerbations.[14]

Atopy

As many as 50% of patients with dyshidrotic eczema have reportedly had personal or familial atopic diathesis (eczema, asthma, hay fever, allergic sinusitis). The serum immunoglobulin E (IgE) level frequently is increased, even in patients who do not report a personal or familial history of atopy. Occasionally, dyshidrotic eczema is the first manifestation of an atopic diathesis.

Nickel sensitivity

This may be a significant factor in dyshidrotic eczema. Nickel sensitivity was reportedly low in some studies of dyshidrosis patients, but significantly elevated in other studies. Increased nickel excretion in the urine has been reported during exacerbations of pompholyx. Ingested metals have been found to provoke exacerbations of pompholyx in some patients.

Low-nickel diets have reportedly decreased the frequency and severity of pompholyx flares. A high palmoplantar perspiration rate has been suggested to result in a local concentration of metal salts that may provoke the vesicular reaction. Contact allergy has been documented in 30% of patients with dyshidrotic eczema.

Cobalt sensitivity

The oral ingestion of cobalt manifests systemic allergic dermatitis as dyshidrotic eczema less frequently than does the oral ingestion of nickel. Much more common is the simultaneous occurrence of nickel and cobalt allergy seen in 25% of nickel-sensitive patients developing pompholyx. In these cases, the eczema is usually more severe. When suspected as the cause of the dyshidrotic eczema, high oral ingestion of cobalt should be taken in consideration, regardless of the patch test results.[5]

A point-based, low-cobalt diet has been proposed to help patients limit cobalt ingestion and to keep the serum level below the threshold for developing flares, which is approximately less than 12 mcg/d. This diet has demonstrated higher compliance than an avoidance diet list. In addition, this diet reduces the amount of nickel consumed.[5]

Exposure to sensitizing chemicals or metals

Dyshidrotic eczema outbreaks are sometimes associated with exposure to sensitizing chemicals or metals (eg, chromium, cobalt, carba mix, fragrance mix, diaminodiphenylmethane, dichromates, benzoisothiazolones, paraphenylenediamine, perfumes, fragrances, balsam of Peru, Primula plant).

Id reaction

Controversy surrounds the possible existence of an id reaction, which is considered to be a distant dermatophyte infection (tinea pedis, kerion of scalp) triggering a palmar pompholyx reaction (also termed pompholyx dermatophytid).

Fungal infection

Pompholyx occasionally resolves when a tinea pedis infection is treated, then relapses when the fungal infection recurs, supporting the existence of this reaction pattern. Of patients who have a vesicular reaction to intradermal trichophytin testing, less than one third have experienced a resolution of pompholyx after treatment with antifungal agents.

Emotional stress

This is a possible factor in dyshidrotic eczema. Many patients report recurrences of pompholyx during stressful periods. Improvement of dyshidrotic eczema using biofeedback techniques for stress reduction supports this hypothesis.

Other factors

Isolated reports describe other possible causative factors, such as aspirin ingestion, oral contraceptives, cigarette smoking, and implanted metals, among others. A 3-year prospective study of the causes of dyshidrotic eczema (pompholyx) in 120 patients found causes of pompholyx related to contact exposure (67.5%), including to cosmetic products (31.7%) and metals (16.7%); interdigital-plantar intertrigo (10%); and internal factors (6.7%), with an additional 15% of patients having undiagnosed (idiopathic) causes probably related to atopic factors.[15]

Contact allergy was found in 89 (74.2%) of the 120 patients. The most frequent allergens were nickel, shower gel, chromium, fragrance, shampoo, and balsam of Peru. Less frequent allergens were lanolin, cobalt, thiuram, lauryl sulfate, fresh tobacco, p -phenylenediamine (PPD), formaldehyde, parabens, and octyl gallate. In 97 of 193 positive patch test results, correlation existed between the application of the agent and pompholyx recurrence. The relevance of the analysis was confirmed in 81 (67.5%) of the 120 patients. In summary, the most frequent causes of pompholyx related to contact with substances were hygiene product intolerance (46.7%), metal allergy (25%), and others (28.3%).

Intertrigo occurred in 19 (15.8%) of the 120 patients. Of those individuals, 80% presented with dermatophytosis and 20% presented with candidiasis. After 3 weeks of antifungal therapy, 6 of 19 patients remained symptomatic for pompholyx.

With regard to internal causes, 30 patients presented with a positive patch test result for metals, but only 2 presented with exacerbations of the lesions after a challenge test.

Of 58 patients with a history of smoking tobacco, 5 presented with a positive reaction, and 2 of those reactions were considered relevant. Drug allergy was determined to be the causative agent in 3 patients (amoxicillin in 2 and intravenous immunoglobulin in 1). Food-related pompholyx was detected in 4 patients, and, after a challenge test, reactivation occurred in 3 of these patients (2 for paprika and 1 for orange juice).

Ultraviolet A light

In a case series, 5 patients with prior diagnosis of pompholyx developed lesions morphologically and histologically consistent with a vesicular dermatitis after provocation with long-wavelength ultraviolet A (UVA) light. Further workup ruled out contact dermatitis, polymorphic light eruption, and heat as the culprit, confirming that the reaction was due to true photosensitivity rather than to photoaggravation.[16]

Pompholyx caused by UVA exposure may possibly be considered a variation of seasonal (summer) pompholyx. In the United States, dyshidrotic eczema is more commonly seen in warmer climates and during the spring and summer months. A study in Turkey also revealed a higher prevalence of dyshidrotic eczema in the summer months.[17]

In a case series, three patients with histories of frequent pompholyx exacerbations, mostly during summer (ie, photoaggavated pompholyx), were subjected to photoprovocation testing, with positive development of pompholyx lesions in two of them. Patients reported lesions after exposure to solar-simulated ultraviolet radiation and broadband UVA. They were treated with photoprotective measures in addition to the standard treatment for pompholyx, resulting in a decrease in the frequency and severity of the exacerbations. The authors suggested that the condition may be underdiagnosed and recommended recognition and early detection to institute sun protection as soon as possible and to avoid starting phototherapy or photochemotherapy in this particular subset of pompholyx patients.[18]

Of interest, UVB phototherapy and photochemotherapy are well-known, efficient treatments for pompholyx.

Previous
Next

Epidemiology

Occurrence in the United States

Dyshidrotic eczema occurs in 5-20% of patients with hand eczema and more commonly develops in warmer climates and during spring and summer months (seasonal or summer pompholyx).

International occurrence

Dyshidrotic eczema accounted for 1% of initial consultations in a 1-year Swedish study. In a study of 107,206 Swedish individuals, 51 (0.05%) were diagnosed with dyshidrosis. Of all hand dermatitis cases in that population, 3% had dyshidrosis.[19]

In a retrospective study reviewing records of 714 Portuguese patients during a 6-year period, Magina et al found dyshidrotic eczema to be the third most common type of hand dermatitis (20.3%).[20]

Sex- and age-related demographics

The male-to-female ratio for dyshidrotic eczema has variably been reported as 1:1 and 1:2. Dyshidrotic eczema affects individuals aged 4-76 years; the mean age is 38 years. The peak incidence of the condition occurs in patients aged 20-40 years. After middle age, the frequency of dyshidrotic eczema episodes tends to decrease.

Previous
 
 
Contributor Information and Disclosures
Author

Sadegh Amini, MD Dermatologist, Hollywood Dermatology; Voluntary Assistant Professor, Department of Dermatology and Cutaneous Surgery, University of Miami, Leonard M Miller School of Medicine; Staff Member, Department of Dermatology, Jackson Memorial Hospital

Sadegh Amini, MD is a member of the following medical societies: American Academy of Dermatology, American Society for Dermatologic Surgery, International Society for Dermatologic Surgery, International Society of Dermatology

Disclosure: Nothing to disclose.

Coauthor(s)

Anne E Burdick, MD, MPH Professor of Dermatology, Director of Leprosy Program, Associate Dean for TeleHealth and Clinical Outreach, University of Miami, Leonard M Miller School of Medicine

Anne E Burdick, MD, MPH is a member of the following medical societies: American Academy of Dermatology, Women's Dermatologic Society

Disclosure: Nothing to disclose.

Camila K Janniger, MD Clinical Professor of Dermatology, Clinical Associate Professor of Pediatrics, Chief of Pediatric Dermatology, Rutgers New Jersey Medical School

Camila K Janniger, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Specialty Editor Board

Richard P Vinson, MD Assistant Clinical Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Texas Medical Association, Association of Military Dermatologists, Texas Dermatological Society

Disclosure: Nothing to disclose.

Paul Krusinski, MD Director of Dermatology, Fletcher Allen Health Care; Professor, Department of Internal Medicine, University of Vermont College of Medicine

Paul Krusinski, MD is a member of the following medical societies: American Academy of Dermatology, American College of Physicians, Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Chief Editor

William D James, MD Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine

William D James, MD is a member of the following medical societies: American Academy of Dermatology, Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Additional Contributors

Kevin P Connelly, DO Clinical Assistant Professor, Department of Pediatrics, Division of General Pediatrics and Emergency Care, Virginia Commonwealth University School of Medicine; Medical Director, Paws for Health Pet Visitation Program of the Richmond SPCA; Pediatric Emergency Physician, Emergency Consultants Inc, Chippenham Medical Center

Kevin P Connelly, DO is a member of the following medical societies: American Academy of Pediatrics, American College of Osteopathic Pediatricians, American Osteopathic Association

Disclosure: Nothing to disclose.

Acknowledgements

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous authors Ivan D Camacho, MD, Julie K Keck, MD, and James D Korb, MD, to the development and writing of the source articles.

References
  1. Hsu CY, Wang YC, Kao CH. Dyshidrosis is a risk factor for herpes zoster. J Eur Acad Dermatol Venereol. 2015 Apr 27. in press. [Medline].

  2. Vocks E, Plotz SG, Ring J. The Dyshidrotic Eczema Area and Severity Index - A score developed for the assessment of dyshidrotic eczema. Dermatology. 1999. 198(3):265-9. [Medline].

  3. Lee WJ, Lee DW, Kim CH, et al. Pompholyx with bile-coloured vesicles in a patient with jaundice: are sweat ducts involved in the development of pompholyx?. J Eur Acad Dermatol Venereol. 2010 Feb. 24(2):235-6. [Medline].

  4. Kontochristopoulos G, Gregoriou S, Agiasofitou E, Nikolakis G, Rigopoulos D, Katsambas A. Letter: regression of relapsing dyshidrotic eczema after treatment of concomitant hyperhidrosis with botulinum toxin-A. Dermatol Surg. 2007 Oct. 33(10):1289-90. [Medline].

  5. Stuckert J, Nedorost S. Low-cobalt diet for dyshidrotic eczema patients. Contact Dermatitis. 2008 Dec. 59(6):361-5. [Medline].

  6. Thierse HJ, Gamerdinger K, Junkes C, Guerreiro N, Weltzien HU. T cell receptor (TCR) interaction with haptens: metal ions as non-classical haptens. Toxicology. 2005 Apr 15. 209(2):101-7. [Medline].

  7. Shenefelt PD. Update on psychodermatological disorders. Expert Rev Dermatol. 2010 Feb. 5(1):95-107.

  8. Gerstenblith MR, Antony AK, Junkins-Hopkins JM, Abuav R. Pompholyx and eczematous reactions associated with intravenous immunoglobulin therapy. J Am Acad Dermatol. 2011 May 19. [Medline].

  9. Kotan D, Erdem T, Acar BA, Boluk A. Dyshidrotic eczema associated with the use of IVIg. BMJ Case Rep. 2013 Feb 15. 2013:[Medline]. [Full Text].

  10. Lee KC, Ladizinski B. Dyshidrotic eczema following intravenous immunoglobulin treatment. CMAJ. 2013 Aug 6. 185(11):E530. [Medline]. [Full Text].

  11. Brazzelli V, Grassi S, Savasta S, Ruffinazzi G, Carugno A, Barbaccia V, et al. Pompholyx of the hands after intravenous immunoglobulin therapy for clinically isolated syndrome: a paediatric case. Int J Immunopathol Pharmacol. 2014 Jan-Mar. 27(1):127-30. [Medline].

  12. Chen JJ, Liang YH, Zhou FS, et al. The gene for a rare autosomal dominant form of pompholyx maps to chromosome 18q22.1-18q22.3. J Invest Dermatol. 2006 Feb. 126(2):300-4. [Medline].

  13. Molin S, Vollmer S, Weiss EH, Ruzicka T, Prinz JC. Filaggrin mutations may confer susceptibility to chronic hand eczema characterized by combined allergic and irritant contact dermatitis. Br J Dermatol. 2009 Oct. 161(4):801-7. [Medline].

  14. Soler DC, Bai X, Ortega L, Pethukova T, Nedorost ST, Popkin DL, et al. The key role of aquaporin 3 and aquaporin 10 in the pathogenesis of pompholyx. Med Hypotheses. 2015 May. 84 (5):498-503. [Medline].

  15. Guillet MH, Wierzbicka E, Guillet S, Dagregorio G, Guillet G. A 3-year causative study of pompholyx in 120 patients. Arch Dermatol. 2007 Dec. 143(12):1504-8. [Medline].

  16. Man I, Ibbotson SH, Ferguson J. Photoinduced pompholyx: a report of 5 cases. J Am Acad Dermatol. 2004 Jan. 50(1):55-60. [Medline].

  17. Tamer E, Ilhan MN, Polat M, Lenk N, Alli N. Prevalence of skin diseases among pediatric patients in Turkey. J Dermatol. 2008 Jul. 35(7):413-8. [Medline].

  18. Nalluri R, Rhodes LE. Photoaggravated pompholyx. Photodermatol Photoimmunol Photomed. 2016 Feb 12. [Medline].

  19. Lofgren SM, Warshaw EM. Dyshidrosis: epidemiology, clinical characteristics, and therapy. Dermatitis. 2006 Dec. 17(4):165-81. [Medline].

  20. Magina S, Barros MA, Ferreira JA, Mesquita-Guimaraes J. Atopy, nickel sensitivity, occupation, and clinical patterns in different types of hand dermatitis. Am J Contact Dermat. 2003 Jun. 14(2):63-8. [Medline].

  21. Iannaccone S, Sferrazza B, Quattrini A, Smirne S, Ferini-Strambi L. Pompholyx (vesicular eczema) after i.v. immunoglobulin therapy for neurologic disease. Neurology. 1999 Sep 22. 53(5):1154-5. [Medline].

  22. Llombart M, Garcia-Abujeta JL, Sanchez-Perez RM, Hernando de Larramendi C. Pompholyx induced by intravenous immunoglobulin therapy. J Investig Allergol Clin Immunol. 2007. 17(4):277-8. [Medline].

  23. Colebunders R, Zolfo M, Lynen L. Severe dyshidrosis in two patients with HIV infection shortly after starting highly active antiretroviral treatment. Dermatol Online J. 2005 Aug 1. 11(2):31. [Medline].

  24. MacConnachie AA, Smith CC. Pompholyx eczema as a manifestation of HIV infection, response to antiretroviral therapy. Acta Derm Venereol. 2007. 87(4):378-9. [Medline].

  25. Molin S, Diepgen TL, Ruzicka T, Prinz JC. Diagnosing chronic hand eczema by an algorithm: a tool for classification in clinical practice. Clin Exp Dermatol. 2011 Aug. 36(6):595-601. [Medline].

  26. Yasuda M, Miyachi Y, Utani A. Two cases of dyshidrosiform pemphigoid with different presentations. Clin Exp Dermatol. 2009 Jul. 34(5):e151-3. [Medline].

  27. Veien NK. Bullous pemphigoid masquerading as recurrent vesicular hand eczema. Acta Derm Venereol. 2010. 90(1):4-5. [Medline].

  28. Chang YY, van der Velden J, van der Wier G, et al. Keratolysis exfoliativa (dyshidrosis lamellosa sicca): a distinct peeling entity. Br J Dermatol. 2012 Nov. 167(5):1076-84. [Medline].

  29. Bittencourt AL, Mota K, Oliveira RF, Farré L. A dyshidrosis-like variant of adult T-cell leukemia/lymphoma with clinicopathological aspects of mycosis fungoides. A case report. Am J Dermatopathol. 2009 Dec. 31(8):834-7. [Medline].

  30. Bittencourt AL, Mota K, Oliveira RF, Farré L. A dyshidrosis-like variant of adult T-cell leukemia/lymphoma with clinicopathological aspects of mycosis fungoides. A case report. Am J Dermatopathol. 2009 Dec. 31(8):834-7. [Medline].

  31. National Institute for Clinical Excellence. Frequency of application of topical corticosteroids for atopic eczema. London, England: National Institute for Clinical Excellence (NICE); 2004. 34.

  32. Wollina U, Abdel Naser MB. Pharmacotherapy of pompholyx. Expert Opin Pharmacother. 2004 Jul. 5(7):1517-22. [Medline].

  33. Boyle RJ, Bath-Hextall FJ, Leonardi-Bee J, Murrell DF, Tang ML. Probiotics for treating eczema. Cochrane Database Syst Rev. 2008 Oct 8. CD006135. [Medline].

  34. Capella GL. Topical khellin and natural sunlight in the outpatient treatment of recalcitrant palmoplantar pompholyx: report of an open pilot study. Dermatology. 2005. 211(4):381-3. [Medline].

  35. Odia S, Vocks E, Rakoski J, Ring J. Successful treatment of dyshidrotic hand eczema using tap water iontophoresis with pulsed direct current. Acta Derm Venereol. 1996 Nov. 76(6):472-4. [Medline].

  36. Markantoni V, Kouris A, Armyra K, Vavouli C, Kontochristopoulos G. Remarkable improvement of relapsing dyshidrotic eczema after treatment of coexistant hyperhidrosis with oxybutynin. Dermatol Ther. 2014 Nov-Dec. 27(6):365-8. [Medline].

  37. Koldys KW, Meyer RP. Biofeedback training in the therapy of dyshidrosis. Cutis. 1979 Aug. 24(2):219-21. [Medline].

  38. Petering H, Breuer C, Herbst R, Kapp A, Werfel T. Comparison of localized high-dose UVA1 irradiation versus topical cream psoralen-UVA for treatment of chronic vesicular dyshidrotic eczema. J Am Acad Dermatol. 2004 Jan. 50(1):68-72. [Medline].

  39. Polderman MC, Govaert JC, le Cessie S, Pavel S. A double-blind placebo-controlled trial of UVA-1 in the treatment of dyshidrotic eczema. Clin Exp Dermatol. 2003 Nov. 28(6):584-7. [Medline].

  40. Tzaneva S, Kittler H, Thallinger C, Honigsmann H, Tanew A. Oral vs. bath PUVA using 8-methoxypsoralen for chronic palmoplantar eczema. Photodermatol Photoimmunol Photomed. 2009 Apr. 25(2):101-5. [Medline].

  41. Sezer E, Etikan I. Local narrowband UVB phototherapy vs. local PUVA in the treatment of chronic hand eczema. Photodermatol Photoimmunol Photomed. 2007 Feb. 23(1):10-4. [Medline].

  42. Schurmeyer-Horst F, Luger TA, Bohm M. Long-term efficacy of occlusive therapy with topical pimecrolimus in severe dyshidrosiform hand and foot eczema. Dermatology. 2007. 214(1):99-100. [Medline].

  43. Wollina U. Pompholyx: what's new?. Expert Opin Investig Drugs. 2008 Jun. 17(6):897-904. [Medline].

  44. Wollina U, Karamfilov T. Adjuvant botulinum toxin A in dyshidrotic hand eczema: a controlled prospective pilot study with left-right comparison. J Eur Acad Dermatol Venereol. 2002 Jan. 16(1):40-2. [Medline].

  45. Egan CA, Rallis TM, Meadows KP, Krueger GG. Low-dose oral methotrexate treatment for recalcitrant palmoplantar pompholyx. J Am Acad Dermatol. 1999 Apr. 40(4):612-4. [Medline].

  46. Petersen CS, Menne T. Cyclosporin A responsive chronic severe vesicular hand eczema. Acta Derm Venereol. 1992 Nov. 72(6):436-7. [Medline].

  47. Ogden S, Clayton TH, Goodfield MJ. Recalcitrant hand pompholyx: variable response to etanercept. Clin Exp Dermatol. 2006 Jan. 31(1):145-6. [Medline].

  48. Menne T, Kaaber K. Treatment of pompholyx due to nickel allergy with chelating agents. Contact Dermatitis. 1978 Oct. 4(5):289-90. [Medline].

  49. Cheer SM, Foster RH. Alitretinoin. Am J Clin Dermatol. 2000 Sep-Oct. 1(5):307-14; discussion 315-6. [Medline].

  50. Ruzicka T, Larsen FG, Galewicz D, et al. Oral alitretinoin (9-cis-retinoic acid) therapy for chronic hand dermatitis in patients refractory to standard therapy: results of a randomized, double-blind, placebo-controlled, multicenter trial. Arch Dermatol. 2004 Dec. 140(12):1453-9. [Medline].

  51. Rongioletti F, Zaccaria E, Viglizzo G. Failure of topical 0.1% alitretinoin gel for classic Kaposi sarcoma: first European experience. Br J Dermatol. 2006 Oct. 155(4):856-7. [Medline].

  52. Baumann L, Vujevich J, Halem M, et al. Open-label pilot study of alitretinoin gel 0.1% in the treatment of photoaging. Cutis. 2005 Jul. 76(1):69-73. [Medline].

  53. Maloney DM, Schmidt JD, Duvic M. Alitretinoin gel to treat pyogenic granuloma. J Am Acad Dermatol. 2002 Dec. 47(6):969-70. [Medline].

  54. Bassiri-Tehrani S, BA BA, Cohen DE. Treatment of cutaneous T-cell lymphoma with alitretinoin gel. Int J Dermatol. 2002 Feb. 41(2):104-6. [Medline].

  55. Bissonnette R, Maares J, Shear N. Alitretinoin is Well Tolerated in the Treatment of Severe Chronic Hand Eczema. Poster P1409 presented a the 68th Annual Meeting of American Academy of Dermatology. March 5-9, 2010, Miami, Fla. J Am Acad Dermatol. Mar 2010. 62(3 Supp):AB51.

  56. Lynde C, Haarsch M, Poulin Y. Alitretinoin is Effective in Clearing Severe Crhonic Hand Ezcema. Poster P1405 presented a the 68th Annual Meeting of American Academy of Dermatology. March 5-9, 2010, Miami, Fla. J Am Acad Dermatol. Mar 2010. 62(3 Supp):AB50.

  57. Maares J. Efficacy and Safety of Alitretinoin in the Treatment of Severe Chronic Hand Eczema Refractory to Topical Therapy. ClinicalTrials.gov identifier: NCT00817063. ClinicalTrials.gov. Available at http://clinicaltrials.gov/ct2/show/study/NCT00817063. Accessed: May 13, 2009.

  58. US Food and Drug Administration. FDA Public Health Advisory. Elidel (pimecrolimus) Cream and Protopic (tacrolimus) Ointment. fda.gov. Available at http://www.fda.gov/cder/drug/advisory/elidel_protopic.htm.. Accessed: May 13, 2009.

  59. US Food and Drug Administration. Pimecrolimus prescribing information. fda.gov. Available at http://www.fda.gov/cder/foi/label/2006/021302s011lbl.pdf.. Accessed: May 13, 2009.

  60. US Food and Drug Administration. Tacrolimus prescribing information. fda.gov. Available at http://www.fda.gov/cder/foi/label/2006/050777s012lbl.pdf.. Accessed: May 13, 2009.

 
Previous
Next
 
Tense vesicles and bullae on the palm. Courtesy of Norman Minars, MD, University of Miami, Department of Dermatology & Cutaneous Surgery.
Close-up view of tense vesicles and bullae of the palm. Courtesy of Norman Minars, MD, University of Miami, Department of Dermatology & Cutaneous Surgery.
Discrete yellow pustules on the sole of the foot. Courtesy of Norman Minars, MD, University of Miami, Department of Dermatology & Cutaneous Surgery.
Multiple tense vesicles on the palm.
Small tense vesicles on the fingers.
Small, discrete, coalesced vesicles on the dorsal hand.
Small, discrete, coalesced vesicles on the fingers.
Palms and soles of a patient with a dyshidrosis flare. The patient unroofed a large bulla on the right sole.
Small discrete vesicles of the lateral fingers.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.